Trial details
Capturing Canadian Real-World Data for AML Chemotherapy Ineligible Patients on Venetoclax
To find out more about this trial and your cancer treatment options, please speak with your doctor.
Trial short name: Abbvie LIVEN
Official title: Capturing Canadian Real-World Data for AML Chemotherapy Ineligible Patients on Venetoclax
Principal Investigator: Dr. Lisa Chodirker
Cancer type: Blood Related
Cancer location: Blood Related
Disease stage: Early Cancer
Trial phase: Other
Intervention: Observational
Registration #:
NCT05424562 
Contact e-mail: cancerclinicaltrials@sunnybrook.ca
Trial description:
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax works to treat AML in adult participants who are ineligible for intensive induction chemotherapy in Canada.
Venetoclax is a drug approved to treat Acute Myeloid Leukemia (AML). All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive induction chemotherapy will be enrolled. Around 270 participants will be enrolled in the study in approximately 15 sites in Canada.
Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 36 months.
There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 36 months.
Main Inclusion Criteria: - Aged ≥ 18 years old - Diagnosis of AML - Ineligible for intensive chemotherapy Potential patients may be approached for consent up to 45 days after initiation of Venetoclax.
